Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03388125

Enrollment

113

Registered

2018-01-02

Start date

2016-01-01

Completion date

2022-12-01

Last updated

2018-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding Esophageal Varices

Brief summary

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Detailed description

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Interventions

DRUGInjection Sclerotherapy

5% ethanolamine oleate group

DRUGN-butyl-2-cyanoacrylate

N-butyl-2-cyanoacrylate injection group

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* cirrhotic patients presented with actively bleeding

Exclusion criteria

* other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with controlled bleeding	6 months	The Number of patients with controlled bleeding

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026